1. ABSTRACT
Background Drug-resistant tuberculosis is a high priority threat to global public health. There are still critical gaps in understanding how novel drug-resistant M. tuberculosis strains emerge and, once emergent, what drives the differential propagation of certain epidemiologically-successful strains over others. This study sought to describe the joint evolutionary and epidemiological histories of a novel multidrug-resistant M. tuberculosis strain recently identified in the capital city of the Republic of Moldova (MDR Ural/4.2).
Methods Using whole genome sequence data and Bayesian phylogenomic methods, we reconstruct the stepwise acquisition of drug-resistance mutations in the MDR Ural/4.2 strain, estimate its historical bacterial population size over time, and infer the migration history of this strain between Eastern European countries.
Results We infer that MDR Ural/4.2 likely evolved (via acquisition of rpoB S450L, which confers resistance to rifampin) in the early 1990s, during a period of social turmoil following Moldovan independence from the Soviet Union. This strain subsequently underwent substantial population size expansion in the early 2000s, at a time when national guidelines encouraged in hospital treatment of TB patients. We infer exportation of this strain and its INH-resistant ancestral precursor from Moldova to neighboring countries starting as early as 1985.
Conclusions Our findings underscore how public health practice and social determinants of health shape the conditions under which M. tuberculosis evolves, and demonstrates how historical changes in these conditions shape present-day challenges in TB control. These findings underscore the need for regional coordination in TB control across Eastern Europe.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the United States National Institutes of Health (NIH T32AI007061 to TSB), the International Union Against Tuberculosis and Lung Disease, and the United States Agency for International Development. None of the funding bodies had any role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Ethical Committee for Research of Phthisiopneumology Institute, Chisinau, Republic of Moldova (Approval Oct 2012), Partners Human Research Committee (2012-P-001904/1), Yale University Human Investigation Committee (IRB number: 1409014628 ), and Columbia University Medical Center (Not Human Subjects Research Under 45 CFR 46).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Whole genome sequencing data for isolates collected in Chişinău, Moldova are available in the National Center for Biotechnology Information Sequence Read Archive (NCBI SRA bioproject number: PRJNA482716). Whole genome sequence data for the regional collection of isolates from eastern Europe are available under NCBI SRA bioproject numbers PRJNA421446, PRJNA429460, PRJNA384815, PRJNA318002, PRJNA480888, and PRJNA482865.
8. LIST OF ABBREVIATIONS
- MDR
- multidrug-resistant;
- TB
- tuberculosis;
- SNP
- single nucleotide polymorphism;
- WGS
- whole genome sequence;
- XDR
- extensively drug-resistant
